Literature DB >> 21514616

Inhibition of Tat-mediated HIV-1 replication and neurotoxicity by novel GSK3-beta inhibitors.

Kylene Kehn-Hall1, Irene Guendel, Lawrence Carpio, Leandros Skaltsounis, Laurent Meijer, Lena Al-Harthi, Joseph P Steiner, Avindra Nath, Olaf Kutsch, Fatah Kashanchi.   

Abstract

The HIV-1 protein Tat is a critical regulator of viral transcription and has also been implicated as a mediator of HIV-1 induced neurotoxicity. Here using a high throughput screening assay, we identified the GSK-3 inhibitor 6BIO, as a Tat-dependent HIV-1 transcriptional inhibitor. Its ability to inhibit HIV-1 transcription was confirmed in TZM-bl cells, with an IC(50) of 40nM. Through screening 6BIO derivatives, we identified 6BIOder, which has a lower IC(50) of 4nM in primary macrophages and 0.5nM in astrocytes infected with HIV-1. 6BIOder displayed an IC(50) value of 0.03nM through in vitro GSK-3β kinase inhibition assays. Finally, we demonstrated 6BIO and 6BIOder have neuroprotective effects on Tat induced cell death in rat mixed hippocampal cultures. Therefore 6BIO and its derivatives are unique compounds which, due to their complex mechanisms of action, are able to inhibit HIV-1 transcription as well as to protect against Tat induced neurotoxicity.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514616      PMCID: PMC3677548          DOI: 10.1016/j.virol.2011.03.025

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  96 in total

Review 1.  Glycogen synthase kinase-3: properties, functions, and regulation.

Authors:  A Ali; K P Hoeflich; J R Woodgett
Journal:  Chem Rev       Date:  2001-08       Impact factor: 60.622

2.  Structural rearrangements of HIV-1 Tat-responsive RNA upon binding of neomycin B.

Authors:  C Faber; H Sticht; K Schweimer; P Rösch
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

3.  Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway.

Authors:  Sharon Amit; Ada Hatzubai; Yaara Birman; Jens S Andersen; Etti Ben-Shushan; Matthias Mann; Yinon Ben-Neriah; Irit Alkalay
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

4.  Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation.

Authors:  K P Hoeflich; J Luo; E A Rubie; M S Tsao; O Jin; J R Woodgett
Journal:  Nature       Date:  2000-07-06       Impact factor: 49.962

5.  Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal.

Authors:  M Hetman; J E Cavanaugh; D Kimelman; Z Xia
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

6.  A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team.

Authors:  R H Haubrich; C Flexner; M M Lederman; M Hirsch; C P Pettinelli; R Ginsberg; P Lietman; F M Hamzeh; S A Spector; D D Richman
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

7.  Evidence for regulation of long terminal repeat transcription by Wnt transcription factor TCF-4 in human astrocytic cells.

Authors:  Bethany Wortman; Nune Darbinian; Bassel E Sawaya; Kamel Khalili; Shohreh Amini
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway.

Authors:  Reena Rao; Chuan-Ming Hao; Matthew D Breyer
Journal:  J Biol Chem       Date:  2003-11-07       Impact factor: 5.157

9.  GSK-3-selective inhibitors derived from Tyrian purple indirubins.

Authors:  Laurent Meijer; Alexios-Leandros Skaltsounis; Prokopios Magiatis; Panagiotis Polychronopoulos; Marie Knockaert; Maryse Leost; Xiaozhou P Ryan; Claudia Alin Vonica; Ali Brivanlou; Rana Dajani; Claudia Crovace; Cataldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Paul Greengard
Journal:  Chem Biol       Date:  2003-12

10.  Intraventricular injection of human immunodeficiency virus type 1 (HIV-1) tat protein causes inflammation, gliosis, apoptosis, and ventricular enlargement.

Authors:  M Jones; K Olafson; M R Del Bigio; J Peeling; A Nath
Journal:  J Neuropathol Exp Neurol       Date:  1998-06       Impact factor: 3.685

View more
  17 in total

1.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

2.  Compounds with species and cell type specific toxicity identified in a 2000 compound drug screen of neural stem cells and rat mixed cortical neurons.

Authors:  Nasir Malik; Anastasia G Efthymiou; Karly Mather; Nathaniel Chester; Xiantao Wang; Avindra Nath; Mahendra S Rao; Joseph P Steiner
Journal:  Neurotoxicology       Date:  2014-10-22       Impact factor: 4.294

3.  Mass spectrometric phosphoproteome analysis of HIV-infected brain reveals novel phosphorylation sites and differential phosphorylation patterns.

Authors:  Lerna Uzasci; Sungyoung Auh; Robert J Cotter; Avindra Nath
Journal:  Proteomics Clin Appl       Date:  2015-08-12       Impact factor: 3.494

Review 4.  Autophagy in dementias.

Authors:  Christine Lund Kragh; Kiren Ubhi; Tony Wyss-Coray; Tony Wyss-Corey; Eliezer Masliah
Journal:  Brain Pathol       Date:  2012-01       Impact factor: 6.508

5.  Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.

Authors:  Irene Guendel; Sergey Iordanskiy; Gavin C Sampey; Rachel Van Duyne; Valerie Calvert; Emanuel Petricoin; Mohammed Saifuddin; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  J Neurovirol       Date:  2015-02-12       Impact factor: 2.643

Review 6.  Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Authors:  Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

7.  Glycogen synthase kinase-3 inhibition rescues sex-dependent contextual fear memory deficit in human immunodeficiency virus-1 transgenic mice.

Authors:  Shamsudheen Moidunny; Michael A Benneyworth; David J Titus; Eleonore Beurel; Udhghatri Kolli; Joyce Meints; Richa Jalodia; Sundaram Ramakrishnan; Coleen M Atkins; Sabita Roy
Journal:  Br J Pharmacol       Date:  2020-11-23       Impact factor: 8.739

Review 8.  Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders.

Authors:  Jerel Fields; Wilmar Dumaop; T D Langford; Edward Rockenstein; E Masliah
Journal:  J Neuroimmune Pharmacol       Date:  2014-02-08       Impact factor: 4.147

9.  Delivery of short interfering ribonucleic acid-complexed magnetic nanoparticles in an oscillating field occurs via caveolae-mediated endocytosis.

Authors:  Jenson Lim; Michael A Clements; Jon Dobson
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

10.  Modulation of GSK-3β activity in Venezuelan equine encephalitis virus infection.

Authors:  Kylene Kehn-Hall; Aarthi Narayanan; Lindsay Lundberg; Gavin Sampey; Chelsea Pinkham; Irene Guendel; Rachel Van Duyne; Svetlana Senina; Kimberly L Schultz; Eric Stavale; M Javad Aman; Charles Bailey; Fatah Kashanchi
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.